COVID_19_VE_Trial_Marker_SAP_26_Apr_2021.pdf (1.96 MB)
USG COVID-19 Response Team / CoVPN Vaccine Efficacy Trial Immune Correlates Statistical Analysis Plan
Version 13 2022-04-18, 18:39
Version 12 2021-07-15, 21:20
Version 11 2021-04-26, 13:59
Version 10 2021-03-15, 16:47
Version 9 2021-02-15, 14:43
Version 8 2021-01-19, 19:34
Version 7 2021-01-18, 17:33
Version 6 2021-01-11, 19:30
Version 5 2021-01-11, 17:44
Version 4 2020-12-07, 14:17
Version 3 2020-12-07, 14:11
Version 2 2020-11-09, 20:25
Version 1 2020-11-06, 03:03
online resource
posted on 2021-04-26, 13:59 authored by USG COVID-19 Response Team / Coronavirus Prevention Network (CoVPN) Biostatistics Team, Peter B. Gilbert, Youyi Fong, David Benkeser, Jessica Andriesen, Bhavesh BorateBhavesh Borate, Marco Carone, Lindsay N. CarppLindsay N. Carpp, Ivan Diaz, Michael P. Fay, Andrew Fiore-GartlandAndrew Fiore-Gartland, Nima S. Hejazi, Ying Huang, Yunda Huang, Ollivier Hyrien, Holly E. Janes, Michal Juraska, Kendrick Li, Alex Luedtke, Martha Nason, April K. Randhawa, Lars van der Laan, Brian Williamson, Wenbo Zhang, Dean FollmannThis Statistical Analysis Plan (SAP) describes the statistical analysis of antibody markers measured at a key time point post last vaccination as correlates of risk and as various types of correlates of protection against primary and secondary endpoints in COVID-19 Prevention Network (CoVPN) COVID-19 vaccine efficacy (VE) trials.
